EugenioCersosimoMD

Endocrinology • San Antonio, TX

Diabetes, Lipid Metabolism

Associate Professor, Medicine, University of Texas Medical School, San Antonio

Join to view full profile

Dr. Cersosimo is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Cersosimo's full profile

Already have an account?

Office
701 S Zarzamora
San Antonio, TX 78207
Phone+1 210-358-7500

Fax+1 210-358-7515

Education & Training

Mayo Clinic College of Medicine and Science (Rochester)Fellowship, Endocrinology, Diabetes, and Metabolism, 1991 - 1994
Mayo Clinic College of Medicine and Science (Rochester)Residency, Internal Medicine, 1988 - 1991
Fluminense Federal University Faculty of MedicineClass of 1974

Certifications & Licensure

TX State Medical License 2002 - 2026
MN State Medical License 1990 - 2003
NY State Medical License 1994 - 2001

Clinical Trials

Mechanisms of Glucose Lowering Effects of Sitagliptin and Metformin Alone and in Combination in Patients With T2DM Start of enrollment: 2009 Oct 01
Completed
Phase 4
Acute Effect of Exenatide on Brain Glucose Metabolism Start of enrollment: 2010 Jul 01
Completed
Phase 4
ESR-15-11293 - Saxa/Dapa, Safety and Efficacy Study Start of enrollment: 2016 Jan 01
Completed
Not Applicable
Effect of Chronic Exenatide Therapy on Beta Cell Function and Insulin Sensitivity in T2DM Start of enrollment: 2017 Dec 15
Completed
Phase 4
Effect of Dapagliflozin on Hepatic and Renal Glucose Metabolism Subjects Start of enrollment: 2019 May 23
Completed
Phase 4
Paradoxical Stimulation of Hepatic Glucose Production With Dapagliflozin Start of enrollment: 2017 Sep 06
Completed
Phase 3
Join now to see all

Publications & Presentations

PubMed

5 citations
Hormonal, Metabolic and Hemodynamic Adaptations to Glycosuria in Type 2 Diabetes Patients Treated with Sodium-Glucose Co-Transporter Inhibitors.
Eugenio Cersosimo, John M. Miles
Current Diabetes Reviews. 2019-07-31
15 citations
Combination therapy with pioglitazone/exenatide/metformin reduces the prevalence of hepatic fibrosis and steatosis: The efficacy and durability of initial combination ...
Olga Lavynenko, Muhammad Abdul-Ghani, Mariam Alatrach, Curtiss Puckett, John Adams
Diabetes, Obesity & Metabolism. 2022-05-01
188 citations
The inflammatory status score including IL-6, TNF-α, osteopontin, fractalkine, MCP-1 and adiponectin underlies whole-body insulin resistance and hyperglycemia in type ...
Giuseppe Daniele, R. Guardado Mendoza, Deidre A. Winnier, Teresa Vanessa Fiorentino, Zuo Pengou
Acta Diabetologica. 2014-02-01

Lectures

Effects of Metformin on Metabolic and Inflammatory Insulin Signaling Pathways in Vascular Smooth Muscle Cell
San Antonio, TX - 6/16/2014

Grant Support

CD Mutations And Type 2 DiabetesNational Center For Research Resources2000–2001
Kidney And Glucose MetabolismNational Institute Of Diabetes And Digestive And Kidney Diseases1994–1998